Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects

Br J Urol. 1979 Aug;51(4):278-82. doi: 10.1111/j.1464-410x.1979.tb04709.x.


Fourteen out of 26 patients with invasive bladder cancer were randomly assigned to receive weekly subcutaneous injections of Corynebacterium parvum (CP) in addition to standard treatment. Peripheral blood T lymphocyte percentage, K cell activity, mitogen responsiveness, and monocyte and polymorph leucotaxis were measured at intervals over a period of 1 to 2 years. The only consistent difference between the CP-treatment patients and the controls was a slightly higher level of K cell activity in the former, who, however, fared rather worse than the controls in terms of survival.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Cell Survival
  • Cells, Cultured
  • Chemotaxis, Leukocyte
  • Clinical Trials as Topic
  • Humans
  • Injections, Subcutaneous
  • Lymphocytes / immunology
  • Mitogens / pharmacology
  • Monocytes / immunology
  • Neutrophils / immunology
  • Propionibacterium acnes / immunology*
  • Urinary Bladder / surgery
  • Urinary Bladder Neoplasms / immunology
  • Urinary Bladder Neoplasms / therapy*


  • Mitogens